How Will Orca-T Impact the Hematologic Oncology Paradigm?
Cancer Network,
Please enable Javascript Following the FDA approval of allogeneic regulatory T cell–containing immunotherapy with hematopoietic…
How Will Orca-T Impact the Hematologic Oncology Paradigm? | CancerNetwork
UBM Medica,
The approval of Orca-T represents a “big advance” that must be studied further, according to Wendy Stock, MD.
FDA Drug Approvals Q2 2026 Medscape Reference5 hours ago
Medscape,
Otolaryngology Otarmeni (lunsotogene parvec) Lunsotogene parvec is an adeno-associated virus vector-based gene therapy…
FDA Approves Orca-T After Phase 3 Trial Improves Chronic GVHD-Free Survival
Consultant Live,
On June 30, 2026, the US Food and Drug Administration (FDA) approved precision-engineered allogeneic regulatory T-cell therapy…